# US 2019/0314270 A1 · Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314270 A1
- Document ID: US20190314270A1
- Status: Published application
- Kind: A1
- Application number: 16/384,645
- Filed: 2019-04-15
- Published: 2019-10-17
- Earliest claimed: 2010-12-23
- Assignees: Rani Therapeutics, LLC
- Applicants: Rani Therapeutics, LLC
- Inventors: Mir Imran
- Web page: https://patentgrep.com/patent/US20190314270A1

## CPC

- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61B 5/073: {Intestinal transmitters}
- A61B 5/14507: {specially adapted for measuring characteristics of body fluids other than blood (devices for taking samples of body liquids A61B10/0045)}
- A61B 5/14539: {for measuring pH}
- A61B 17/12099: {characterised by the location of the occluder}
- A61B 17/12136: {Balloons}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61M 5/00: Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests (tube connectors, tube couplings, valves or branch units, specially adapted for medical use A61M39/00; containers specially adapted for medical or pharmaceutical purposes A61J1/00)
- A61M 5/14276: {specially adapted for implantation}
- A61M 25/10: Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00})
- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- A61B 5/6861: {Capsules, e.g. for swallowing or implanting}
- A61B 2017/00345: {Micromachines, nanomachines, microsystems}
- A61B 2017/00818: {Treatment of the gastro-intestinal system}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61M 2005/14284: {with needle insertion means}
- A61M 2205/02: characterised by a particular materials
- A61M 2205/13: with means for the detection of operative contact with patient, e.g. lip sensor
- A61M 2205/3324: PH measuring means
- A61M 2205/6009: for matching patient with his treatment, e.g. to improve transfusion security
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for delivering a etanercept to a patient in need thereof, the method comprising:
orally delivering a dosage of etanercept contained within a tissue penetrating member into a lumen of the GI-tract of the patient in a manner wherein the etanercept is not degraded by digestive fluids within the GI tract lumen; and
advancing the tissue penetrating member into a gastro-intestinal wall to penetrate the tissue penetrating member into the gastro-intestinal wall, wherein the etanercept is released into the patient's blood stream in a biologically active form.

### Claim 3 (depends on 2)

The method of claim 2, wherein the tissue penetrating member is advanced into the gastro-intestinal wall by the application of a mechanical force on a surface of the tissue penetrating member.

### Claim 4 (depends on 2)

The method of claim 2, wherein the tissue penetrating member is advanced into the gastro-intestinal wall responsive to a condition in the gastro-intestinal tract.

### Claim 5 (depends on 4)

The method of claim 4, wherein the condition is a pH.

### Claim 6 (depends on 2)

The method of claim 2, wherein the gastro-intestinal wall is the stomach wall.

### Claim 7 (depends on 2)

The method of claim 2, wherein the gastro-intestinal wall is the wall of the small intestine.

### Claim 8 (depends on 2)

The method of claim 2, wherein the dosage of etanercept comprises at least one pharmaceutical excipient.

### Claim 9 (depends on 8)

The method claim 8, wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant.

### Claim 10 (depends on 9)

A method as in claim 9, wherein the binder comprises PEG.

### Claim 11 (depends on 2)

The method of claim 2, wherein the tissue penetrating member comprises a biodegradable material which degrades within the gastro-intestinal wall to release the etanercept into the blood stream.

### Claim 12 (depends on 11)

The method of claim 11, wherein the gastro-intestinal wall is the wall of the small intestine and the tissue penetrating member degrades within the wall of the small intestine to release the etanercept into the blood stream.

### Claim 13 (depends on 2)

The method of claim 2, wherein the dosage of Etanercept in the tissue penetrating member is in a range from about 1 to 5 mg.

### Claim 14 (depends on 13)

The method of claim 13, wherein the dosage of Etanercept is in a range from about 2 to about 4 mg.

### Claim 15 (depends on 2)

A method as in claim 2, further comprising retaining the solid dosage Etanercept within the intestinal wall after insertion

### Claim 16 (depends on 2)

The method of claim 2, wherein the Etanercept solid dosage produces a long-term release of Etanercept.

### Claim 17 (depends on 16)

The method of claim 16, wherein the long term release is over a period of about 6 to 24 hours.

### Claim 18 (depends on 2)

The method of claim 2, further comprising: using the dosage of delivered etanercept to treat an autoimmune disease in the patient.

### Claim 19 (depends on 18)

The method of claim 18, where the autoimmune disease is rheumatoid arthritis.

### Claim 20 (depends on 18)

The method of claim 18, where the autoimmune disease is psoriatic arthritis.

### Claim 21 (depends on 18)

The method of claim 18, where the autoimmune disease is ankylosing spondylitis.

### Claim 22 (depends on 18)

The method of claim 18, where the autoimmune disease is juvenile idiopathic arthritis.

### Claim 23 (depends on 2)

The method of claim 2, wherein tissue penetrating member is contained in a swallowable enclosure and operably coupled to an actuator having a first configuration and a second configuration, the solid dosage being contained within the enclosure in the first configuration and advanced out of the enclosure and into the gastro-intestinal wall in the second configuration.

### Claim 24 (depends on 23)

The method of claim 23, wherein the swallowable enclosure comprises a swallowable capsule.
